Table 3.

Clinical course of patients who underwent conversion surgery.

	Age	Sex	Primary site	Initial metastatic sites	Systemic therapy before conversion surgery	Objective response according to RECIST 1.1	Reason that makes the disease resectable	BRAF V600E and SRC status	Genetic alterations of EGFR pathwaya	Pattern of failure after conversion surgery	Months after primary tumor resection	Alive or death
1	53	F	Rectosigmoid	Liver	FOLFOX + Pmab	−72%	Significant shrinkage of liver metastases	All wild-type	All wild-type	Lung	27	Alive (NED)b
2	59	F	Sigmoid	Liver	FOLFOX + Pmab	−71%	Significant shrinkage of liver metastases	All wild-type	All wild-type	Liver	27	Alive (Tumor bearing)
3	66	F	Rectosigmoid	Liver	XELOX + Bmab	−62%	Significant shrinkage of liver metastases	All wild-type	All wild-type	Liver	52	Alive (NED)c
4	50	F	Sigmoid	Liver	XELOX + Bmab	−44%	Significant shrinkage of liver metastases	All wild-type	Mutant	Liver	51	Alive (Tumor bearing)
5	48	F	Sigmoid	Liver and distant LN	FOLFOX + Bmab	−38%	Significant shrinkage of liver metastases (especially near the inferior vena cava)	All wild-type	All wild-type	Liver	49	Dead
6	51	M	Sigmoid	Liver	XELOX + Bmab	−72%	Significant shrinkage of liver metastases	All wild-type	Mutant	Liver	46	Dead
7	56	M	Sigmoid	Liver	XELOX + Bmab	−43%	Significant shrinkage of liver metastases	All wild-type	All wild-type	Liver	35	Dead
8	76	M	Transverse	Liver	FOLFOX + Bmab	−32%	Significant shrinkage of liver metastases (especially near the inferior vena cava)	All wild-type	Mutant	Liver	34	Dead
9	75	F	Sigmoid	Liver	XELOX + Bmab	−45%	Significant shrinkage of liver metastases	All wild-type	All wild-type	Lung	41	Dead
10	78	F	Sigmoid	Liver and lung	FOLFOX	−28%	Significant shrinkage of liver metastases	All wild-type	All wild-type	Liver and peritoneum	72	Dead
11	45	M	Ascending	Liver and peritoneum	FOLFOX	−40%	Significant shrinkage of liver metastases	All wild-type	Mutant	Liver and lung	47	Dead

Bmab Bevacizumab, FOLFOX 5FU + Leucovorin + Oxaliplatin, Pmab Panitumumab, LN lymph node, NED no evidence of disease, XELOX XELODA + Oxaliplatin.

^aGenetic alterations of EGFR pathway: Genetic alterations of TK receptors (ERBB2, MET, EGFR, FGFR1, and PDGFRA), MEK/ERK pathway (KRAS, NRAS, HRAS, BRAF, and MAPK2K1), and PI3K pathway (PTEN and PIK3CA).

^bThis patient underwent metastasectomies three times (lung, liver, liver) after conversion surgery.

^cThis patient underwent metastasectomies three times (liver, liver, liver) after conversion surgery.